Toxicities for 16 patients treated with 19-28z CAR EBV-VSTs
| Event (CTCAE grade) . | Overall cohort, n (%) . | Third-party donor cohort, n (%) . |
|---|---|---|
| Number | 16 | 12 |
| CRS (grade 1) | 1 (6) | 1 (8) |
| Neurotoxicity | 2 (13) | 2 (13) |
| Irritability (grade 2) | 1 (6) | 1 (8) |
| Headache (grade 1) | 1 (6) | 1 (8) |
| Skin GVHD (grade 1) | 1 (6) | 1 (8) |
| Skin GVHD (grade 2) | 1 (6) | 1 (8) |
| Skin GVHD (grade 3) | 1 (6) | |
| Non-GVHD skin rash (grade 1) | 2 (12) | |
| Non-GVHD skin rash (grade 2) | 2 (12) | 2 (17) |
| Febrile neutropenia (grade 3) | 1 (6) | |
| Pneumonitis (grade 3) | 1 (6) | 1 (8) |
| Bone pain (grade 1) | 1 (6) | 1 (8) |
| Weight loss (grade 1) | 1 (6) | 1 (8) |
| Vomiting (grade 1) | 1 (6) | 1 (8) |
| Event (CTCAE grade) . | Overall cohort, n (%) . | Third-party donor cohort, n (%) . |
|---|---|---|
| Number | 16 | 12 |
| CRS (grade 1) | 1 (6) | 1 (8) |
| Neurotoxicity | 2 (13) | 2 (13) |
| Irritability (grade 2) | 1 (6) | 1 (8) |
| Headache (grade 1) | 1 (6) | 1 (8) |
| Skin GVHD (grade 1) | 1 (6) | 1 (8) |
| Skin GVHD (grade 2) | 1 (6) | 1 (8) |
| Skin GVHD (grade 3) | 1 (6) | |
| Non-GVHD skin rash (grade 1) | 2 (12) | |
| Non-GVHD skin rash (grade 2) | 2 (12) | 2 (17) |
| Febrile neutropenia (grade 3) | 1 (6) | |
| Pneumonitis (grade 3) | 1 (6) | 1 (8) |
| Bone pain (grade 1) | 1 (6) | 1 (8) |
| Weight loss (grade 1) | 1 (6) | 1 (8) |
| Vomiting (grade 1) | 1 (6) | 1 (8) |